In addition, TIME also contains a variety of potential cancer therapeutic targets, such as CTLA-4 and PD-1/PD-L1, and other immune checkpoint blockade-related targets are the current hot spots for tumor targeted therapy (15). Here, CD274 is linked to neoplasm.